Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mucogel oral suspension
0101010G0BCABAB
|
Mucogel | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | 4,511 |
|
Co-magaldrox 195mg/220mg/5ml oral suspension sugar free
0101010G0AAABAB
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | 3,184 |
|
Maalox 175mg/200mg/5ml oral suspension
0101010G0BBAHAG
|
Maalox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | 738 |
|
Co-magaldrox 200mg/175mg/5ml oral suspension sugar free
0101010G0AAAGAG
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | 387 |
|
Maalox oral suspension
0101010G0BBABAB
|
Maalox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | 6 |
|
Co-magaldrox 300mg/600mg tablets
0101010G0AAADAD
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
|
Co-magaldrox 300mg/600mg/5ml oral suspension sugar free
0101010G0AAACAC
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
|
Maalox TC oral suspension
0101010G0BBACAC
|
Maalox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
|
Maalox TC tablets
0101010G0BBADAD
|
Maalox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.